Diffuse Expression of RNA-Binding Protein IMP3 Predicts High-Stage Lymph Node Metastasis and Poor Prognosis in Colorectal Adenocarcinoma

Yuan, Ray-Hwang; Wang, Chi-Chao; Chou, Cheng‐Chun; Chang, King‐Jen; Lee, Po‐Huang; Jeng, Yung‐Ming

doi:10.1245/s10434-009-0446-0

Cited by 45 publications

(53 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, our results showed a relationship between the grade of the tumor differentiation and IMP3 immunoreactivity, while this relationship was not found by the studies of Lin et al (23), Li et al (24) and Yuan et al (25). Consistent with the study of Lochhead et al (22) and Lin et al (23) and in contrast with the research of Yuan et al (25), there was no relationship between tumor size and the grade of tumor differentiation in the present study. In contrast with the study of Lochhead et al (22) and Lin et al (23) an insignificant correlation between the depth of tumor and lymph node involvement was found.…”

Section: Discussionsupporting

confidence: 90%

“…It has been reported that IGF2BP3 is a prognostic and diagnostic biomarker in many tumoral tissues including colorectal adenocarcinoma (22)(23)(24)(25). We stained 112 formalin fixed paraffin embedded colorectal tumor tissues (NOS type) with an immunohistochemistry method and showed that 50% of these tumors were cytoplasmically positive for IMP3.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

The Relationship Between IMP3 Expression in Colorectal Adenocarcinoma and Clinicopathologic Findings

Radfar¹,

Achak²,

Rajaei³

2015

Biotech Health Sci

View full text Add to dashboard Cite

Background:The IMP3 is an oncofetal protein, which has been recently proposed as a diagnostic and prognostic marker in many cancers, including colorectal adenocarcinoma. The overexpression of IMP3 seems to have a correlation with patient's prognosis. Objectives: In this study, the relationship between IMP3 expression in colorectal adenocarcinoma and clinicopathologic findings was assessed. Patients and Methods:In this study 112 colorectal tumor paraffin blocks of Rasoul-e-Akram hospital were stained for IMP3 and slides were assessed for intensity and extent of positivity. The statistical relationships between marker expression and clinicopathologic findings (degree of differentiation, tumor size, depth of invasion and lymph nodes metastasis) were assessed. Data were analyzed by the SPSS 21 software and logistic regression and chi-square test, with p-values of less than 0.05 indicating statistical significance. Results: Immunoreactivity pattern of IMP3 was cytoplasmic in different clinicopathologic findings. Among different clinicopathologic findings, we found a statistical relationship between tumor differentiation and IMP3 (P = 0.047); so that, the poorly differentiated tumors were positive for this marker. No relationship was found between tumor size, depth of invasion or lymph node involvement and IMP3. Conclusions: IMP3 immunoreactivity was associated with poor differentiation of tumor yet not associated with tumor size depth of invasion or lymph node involvement.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 96%

The Relationship Between IMP3 Expression in Colorectal Adenocarcinoma and Clinicopathologic Findings

Radfar¹,

Achak²,

Rajaei³

2015

Biotech Health Sci

View full text Add to dashboard Cite

show abstract

“…(9,10,(12)(13)(14)(30)(31)(32) Vikesaa et al also showed that IMP3 could regulate the adhesion and invasion of HeLa cells by directly targeting CD44 in the formation of invadopodia. (11) In our previous study, we showed that IMP3 expression promoted tumor invasion and predicted early recurrence and poor prognosis in hepatocellular carcinoma and that the invasion ability could be suppressed by depletion of IMP3 expression in vitro by RNAi.…”

Section: Discussionmentioning

confidence: 99%

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

Chen

Jeng

Chang³

et al. 2011

Cancer Science

Self Cite

View full text Add to dashboard Cite

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been reported to enhance proliferation and invasion in various cancers. The role of IMP3 on neuroblastoma (NB) is unknown. We aimed to clarify the prognostic significance of IMP3 expression in patients with NB. By microarray analysis, high IMP3 expression was found in patients with poor outcome. IMP3 expression in 90 NB samples was analyzed by immunohistochemical staining to correlate with clinical stages, histology, and patient outcome. Positive IMP3 expression was detected in 52 of 90 patients, and was significantly correlated with undifferentiated histology, advanced stages, MYCN amplification, and poor outcome. In subgroups, positive IMP3 expression could predict an even worse prognosis in patients with advanced disease, with normal MYCN status, or with MYCN amplification (P = 0.005, P = 0.001, and P = 0.033, respectively). The IMP3 expression decreased by induction of differentiation with retinoid acid treatment in SK-N-DZ and SK-N-SH cells in vitro. The invasion ability of NB cells also decreased as IMP3 knockdown by using RNA interference in vitro. In summary, high expression of IMP3 in NB might contribute to the undifferentiated phenotype and invasive behaviors, leading to a poor prognosis. Determining IMP3 expression in NB could help to improve a personalized therapy. (Cancer Sci 2011; 102: 2191-2198 N euroblastoma (NB), a common cancer of early childhood that originates from primitive sympathetic neural precursors, has a remarkable heterogeneity of clinical behaviors ranging from spontaneous regression to rapid progression and death. Therapeutic options are proposed according to the Children's Oncology Group risk stratification criteria based on clinical and biological factors, including clinical stage, MYCN status, age at diagnosis, histology, and ploidy status.(1,2) Treatment strategy, which ranges from observation alone to intensive multimodal therapy, depends on the risk stratification of the patient in one of the three subgroups of low-, intermediate-, and high-risk of death. Although several biological and molecular prognostic factors have been identified, amplification of the MYCN oncogene, which occurs in roughly 20% of primary NB, is one of the most powerful prognostic factors in NB.(3) The co-opting neurotrophin pathways including the neurotrophin receptors (TrkA, TrkB, and TrkC) and their ligands (NGF, BDNF, and neurotrophin-3, respectively), which regulate the differentiation, apoptosis, and growth of neural cells, are also important prognosis-related factors in NB.(4) However, some patients with a normal MYCN copy number still present with clinically aggressive progression similar to those with MYCN-amplified tumors, suggesting that other unfavorable molecules determining inferior survival may exist.(5,6)The insulin-like growth factor II mRNA-binding protein 3 (IMP3), also known as L532S or K homology domain-containing protein overexpressed in cancer (KOC), is a member of the RNA-binding protein family that includes IMP1, IMP2...

show abstract

“…Several studies have shown that IMP3 is associated with aggressive and advanced carcinomas in colon, kidney, neuroendocrine skin (Merkel cell carcinoma), liver, bladder, ovary, and in soft tissue sarcomas [16][17][18][19][20][21][22][23][24][25]. On the basis of these results, IMP3 may be a useful prognostic factor in many malignant solid tumors.…”

Section: Introductionmentioning

confidence: 99%

Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues

et al. 2009

View full text Add to dashboard Cite

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein highly expressed in fetal tissue and malignant tumors but rarely found in adult benign tissues. In various tumors, IMP3 expression is correlated with increased tumor aggressiveness and reduced overall survival. To our knowledge, IMP3 expression has not been investigated in pituitary tumors. We analyzed the immunohistochemical expression of IMP3 in five normal pituitary tissues and 75 pituitary tumors (64 adenomas and 11 carcinomas) to determine if specific tumor types expressed IMP3 and if there were differences in IMP3 expression between adenomas and carcinomas. Immunohistochemical analysis showed that IMP3 was positive in four (80%) normal pituitaries with focal stain in a subset of normal anterior pituitary cells. IMP3 was expressed in 31% (20/64) of adenomas and in 36% (4/11) of carcinomas. A slightly higher level of IMP3 expression was observed in PRL-GH-TSH adenomas compared to the other types of pituitary adenomas. Expression of IMP3 was not significantly higher in carcinomas than in adenomas (p = 0.737). RT-PCR and Western Blotting supported the heterogeneous expression of IMP3. These results indicate that IMP3 is expressed both in normal and in neoplastic pituitary gland tissues without significant differences in expression levels in pituitary carcinomas.

show abstract

Diffuse Expression of RNA-Binding Protein IMP3 Predicts High-Stage Lymph Node Metastasis and Poor Prognosis in Colorectal Adenocarcinoma

Abstract: Diffuse IMP3 protein expression correlates with invasion and aggressiveness during cancer growth and metastasis, and it is an important prognostic factor of CRAs.

Cited by 45 publications

References 34 publications

The Relationship Between IMP3 Expression in Colorectal Adenocarcinoma and Clinicopathologic Findings

The Relationship Between IMP3 Expression in Colorectal Adenocarcinoma and Clinicopathologic Findings

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues

Contact Info

Product

Resources

About